Coronavirus: Maharashtra bans sale of ‘Coronil’; seeks clinical trial

Mumbai: Amid the controversy over the yoga guru Baba Ramdev’s company Patanjali Ayurved introducing a self-touted “cure” for coronavirus infection, the Maharashtra state government has said that it will not allow the sale of “spurious medicines” in the state unless the National Institute of Medical Sciences, Jaipur finds out whether clinical trials of ‘Coronil’ were done at all.

Maharashtra Home Minister on his Twitter fired, “An abundant warning to Baba Ramdev that Maharashtra won’t allow the sale of spurious medicines.”

Meanwhile, the Uttarakhand state government is serving a notice to Patanjali Ayurved for launching a drug claiming to be a cure for COVID-19 when it had only applied for a licence to manufacture an immunity booster against cough and fever.

The revelation from the state comes even as the AYUSH ministry at the Centre prepares to examine the herbal products company’s documents on research and the composition of the drug developed by it. Union Minister Shripad Naik said Patanjali coming with the medicine was a “good initiative” but due process has to be followed.

Hours after the launch of Coronil, the Union AYUSH Ministry had asked the firm to provide the details, telling it to stop advertising it till the issue is examined.

Naik said Patanjali Ayurved has submitted the documents. The reports which were sent to the ministry on Tuesday will be examined, he said. At a time when everybody is grappling for a cure for COVID-19, such an initiative is surely good but then the due process has to be followed, the minister said.

Uttarakhand’s Ayurved department’s licence officer Y S Rawat said the notice is being issued to the firm to explain from where it got the permission to launch a ‘corona kit’ as a cure for the virus. Patanjali Ayurved Ltd had the licence only for manufacturing an immunity booster against cough and fever. There was nothing in their application related to the treatment of coronavirus, the official said.

Related Articles

Back to top button
Close
Close